How much is ILiAD Biotechnologies worth in 2026?

ILiAD Biotechnologies has a current valuation of N/A based on their Later Stage VC (Series B) round and secondary market data.

How much funding has ILiAD Biotechnologies raised?

ILiAD Biotechnologies has raised N/A in total funding across 1 funding rounds.

ILiAD Biotechnologies

Drug Discovery

ILiAD Biotechnologies valuation and funding history | Last updated: February 10, 2026 | 1 funding rounds

Current Valuation

N/A

As of February 10, 2026

Total Funding Raised

N/A

Across 1 round

Last Round

Later Stage VC (Series B)

$115.0M

Last Funding

Feb 2026

Funding date

Capital Efficiency

N/A

Valuation / Funding

Funding History & Valuation Timeline

Complete history of all funding rounds and valuation milestones

Date	Round	Amount	Post-Valuation	Growth
February 10, 2026	Later Stage VC (Series B)	$115.0M	N/A	-

Valuation Analysis

Current Valuation Metrics

ILiAD Biotechnologies is currently valued at N/A as of February 10, 2026.

Track ILiAD Biotechnologies Valuation Updates

Get notified when ILiAD Biotechnologies raises new funding or valuation changes

Explore More Data

Detailed analysis for ILiAD Biotechnologies

Secondary Market Price

Real-time pricing data and trends

Valuation Tracker

Historical valuation changes

Funding History

Complete funding round timeline

Secondary Price History

Historical transaction data

All Investors

Complete list of all investors

View 5 companies free

Create a free account to unlock ILiAD Biotechnologies's valuation history, funding rounds, and growth metrics.

No credit card required

What is ILiAD Biotechnologies Worth in 2026?

ILiAD Biotechnologies is a leading private company in the Drug Discovery sector. Track ILiAD Biotechnologies's valuation history, funding timeline, and implied market value from secondary transactions on Premier Alternatives.

How ILiAD Biotechnologies Valuation is Determined

Private company valuations like ILiAD Biotechnologies's are determined through primary funding rounds led by venture capital firms, private equity investors, and strategic partners. The valuation reflects factors including revenue growth, market opportunity, competitive positioning, and investor sentiment.